Former CEO faces lawsuit in New York for insider trading related to COVID vaccine contamination

significant action to improve transparency and integrity” throughout its operations.
The civil lawsuit filed against Robert Kramer, the former CEO of Emergent BioSolutions, by New York Attorney General Letitia James alleges that he engaged in insider trading. Kramer stands accused of selling the company’s stock while being aware of contamination issues at a Baltimore plant responsible for manufacturing COVID-19 vaccines. According to the lawsuit, Kramer violated the Martin Act, a state securities law, and made an illegal profit of $10.12 million by using a 10b5-1 stock trading plan that he implemented after learning about tainted AstraZeneca vaccine batches at the Emergent plant in October 2020.
Kramer’s stock sales came to an end just before Emergent faced a decline in its share price due to mounting concerns about the plant. The company, which is headquartered in Gaithersburg, Maryland, has agreed to pay a civil fine of $900,000 for approving Kramer’s trading plan and has committed to strengthening its insider trading policy.
In response to the allegations, Kramer’s attorney, Kirby Behre, dismissed the lawsuit as baseless and unwarranted. Behre maintained that Kramer had adhered to all company protocols and federal regulations related to 10b5-1 plans. He expressed confidence that the facts would reveal that the lawsuit against his client should never have been initiated.
Emergent has emphasized its efforts to enhance transparency and ethics across its operations. These actions have been taken in response to the allegations of insider trading and the contamination issues that plagued the Baltimore plant where vaccine production was suspended in April 2021.
Insider trading occurs when corporate executives utilize non-public information to trade stocks illegally, violating the public’s trust. Attorney General Letitia James underscored the unethical and unlawful nature of Kramer’s actions, highlighting the breach of trust inherent in using insider information for personal financial gain. Kramer had retired from Emergent in June 2023, and Attorney General James filed her complaint in a New York state court in Manhattan.
Following the completion of his stock sales, Emergent’s share price plummeted by approximately 90%. The fallout from the contamination problems and insider trading allegations has had a significant impact on the company’s financial standing. The case against Kramer serves as a stark reminder of the legal and ethical boundaries that corporate executives must respect when handling sensitive information and trading company stocks.
Overall, the lawsuit against Robert Kramer sheds light on the repercussions of insider trading and the importance of upholding transparency and integrity in corporate practices. As the legal proceedings unfold, the case will continue to underscore the consequences of breaching securities laws and engaging in illicit financial activities.